FinEdge Labs
B

BMY

BMYUnverified
27 segments tracked|8 years of data|Annual (10-K)
Total Revenue
$230.1B93.4%
FY2024
Operating Segments
27
Active segments
Blended Margin
0.0%
Operating margin
Highest Margin
0.0%
Sales Revenue Gross
Segment Shift

Sales Revenue Gross has grown from 0.0% to 36.4% of total revenue since FY2017, with 0.0% operating margins. Meanwhile, Augtyro is the fastest growing at +3700.0% YoY.

Segment Revenue Over Time

Revenue Mix

Segment Breakdown — FY2024

SegmentRevenueOp. IncomeMargin% of TotalYoY
Sales Revenue Gross$83.7B$00.0%36.4%+13.6%
Net Product Sales$46.8B$00.0%20.3%+0.0%
Legacy Brands$25.7B$00.0%11.2%+0.0%
Growth Brands$22.6B$00.0%9.8%+0.0%
Eliquis$13.3B$00.0%5.8%+9.2%
Opdivo$9.3B$00.0%4.0%+3.3%
Revlimid$5.8B$00.0%2.5%-5.3%
Orencia$3.7B$00.0%1.6%+2.2%
Pomalyst Imnovid$3.5B$00.0%1.5%+3.0%
Yervoy$2.5B$00.0%1.1%+13.0%
Reblozyl$1.8B$00.0%0.8%+75.9%
Other Growth Brands$1.6B$00.0%0.7%+0.0%
Allianceandotherrevenues$1.5B$00.0%0.7%+23.9%
Sprycel$1.3B$00.0%0.6%-33.4%
Other Revenues$1.0B$00.0%0.5%+68.2%
Opdualag$928M$00.0%0.4%+48.0%
Other Legacy Brands$925M$00.0%0.4%+0.0%
Abraxane$875M$00.0%0.4%-12.8%
Breyanzi$747M$00.0%0.3%+105.2%
Camzyos$602M$00.0%0.3%+160.6%
Zeposia$566M$00.0%0.2%+30.4%
Alliance Revenues$479M$00.0%0.2%-21.2%
Abecma$406M$00.0%0.2%-14.0%
Sotyktu$246M$00.0%0.1%+44.7%
Krazati$126M$00.0%0.1%+0.0%
Augtyro$38M$00.0%0.0%+3700.0%
Cobenfy$10M$00.0%0.0%+0.0%

Want more? Unlock the full analysis.

Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.

Get Started Free